PF-06465469 (Standard)
PF-06465469 (Standard) is the analytical standard of PF-06465469 (HY-108691). This product is intended for research and analytical applications. PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma.
For research use only. We do not sell to patients.
- CAS No.: 1407966-77-1
- Formula: C30H33N7O2
- Molecular Weight:523.63
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
-
HY-108691
PF-06465469ITK Inhibitor -
HY-11092
BMS-509744ITK Inhibitor -
HY-120559
GSK-2250665AItk Inhibitor -
HY-112161
BranebrutinibBTK Inhibitor -
HY-12680
PRN694ITK/RLK Inhibitor -
HY-101856
BMS-986142BTK Inhibitor -
HY-128726
ITK inhibitor 2ITK Inhibitor -
HY-12410
GNE-9822ITK Inhibitor -
HY-109078
VecabrutinibBTK/ITK Inhibitor -
HY-110113
CTA056ITK inhibitor -
HY-16984
GNE-4997ITK Inhibitor -
HY-101856R
BMS-986142 (Standard)Reference Standard
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1407966-77-1
-
Molecular Weight 523.63
-
Formula C30H33N7O2
-
SMILES
O=C(NC1=CC=C(C(C)C)C(C)=C1)C2=CC=CC(C3=NN([C@H]4CN(C(C=C)=O)CCC4)C5=NC=NC(N)=C53)=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
Hot Topics
-
All
-
Topics
-
Most Recent
-
Oldest
-
Topics CAR-T Cell Therapy & Neurodegenerative Diseases
Chimeric antigen receptor T-cell (CAR-T) therapy is an adoptive cellular immunotherapy originally developed for cancer treatment and is now being explored for neurodegenerative diseases, particularly Alzheimer’s disease.
2026-06-18
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PF-06465469 (Standard) Related Classifications
HY-108691R Related Classifications
Powered by Bioz
Keywords
- PF-06465469 (Standard)
- 1407966-77-1
- Reference Standards
- Itk
- Btk
- CXCR
- PD-1/PD-L1
- LAG-3
- Interleukin-2 inducible T-cell kinase
- IL2 inducible T-cell kinase
- Bruton tyrosine kinase
- CXC chemokine receptors
- C-X-C motif chemokine receptors
- PD-1/Programmed death-ligand 1
- Lymphocyte activation gene-3
- CD223
- Jurkat cells
- CAR-T cells
- MEC1 cells
- migration.
- Inhibitor
- inhibitor
- inhibit